1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Dopamine Receptor

Dopamine Receptor

Dopamine Receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. Dopamine receptors are implicated in many neurological processes, including motivation, pleasure, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders. Thus, dopamine receptors are common neurologic drug targets; antipsychotics are often dopamine receptor antagonists while psychostimulants are typically indirect agonists of dopamine receptors. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4receptors are members of the D2-like family.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-126068
    Esamisulpride
    Antagonist 99.04%
    Esamisulpride ((S)-Amisulpride) is the S-isomer of Amisulpride (HY-14545). Esamisulpride is a potent dopamine D2/D3 receptor antagonist with Ki values of 4.43 nM for D2R and 0.72 nM for D3R. Esamisulpride is a 5-HT7 receptor antagonist with a Ki of 900 nM. Esamisulpride can be used in the research of schizophrenia and depression.
    Esamisulpride
  • HY-158243
    Fallypride precursor
    Antagonist 98.92%
    Fallypride precursor (Compound 15) can be used for synthesis of Fallypride (HY-135497). Fallypride is an antagonist of the dopamine D2/D3 receptor. Fallypride can be used as a positron emission tomography (PET) radiotracer when labeled with 18F.
    Fallypride precursor
  • HY-116181
    YQA14
    98.62%
    YQA14 is a high affinity dopamine D3 receptor antagonist. YQA14 is anti-opioid addiction agent. YQA14 inhibits Morphine/Cocaine-induced conditioned place preference (CPP) in animals.
    YQA14
  • HY-103412
    SKF 83959 hydrobromide
    Agonist 99.86%
    SKF83959 hydrobromide is a potent and selective dopamine D1-like receptor partial agonist. SKF83959 hydrobromide Ki values for rat D1, D5, D2 and D3 receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 hydrobromide is a potent allosteric modulator of sigma (σ)-1 receptor. SKF83959 hydrobromide belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 hydrobromide can be used for the research of Alzheimer's disease and depression.
    SKF 83959 hydrobromide
  • HY-B1164
    Bromopride
    Antagonist 99.87%
    Bromopride is a selective, irreversible, competitive, and orally effective dopamine D2 receptor antagonist. Bromopride can pass through the blood-brain barrier, inhibit the vomiting center, and enhance gastrointestinal motility, exerting antiemetic and gastrointestinal motility effects. Bromopride antagonizes dopamine-mediated vomiting reflexes and promotes gastrointestinal smooth muscle contraction, and has no adverse effects on abdominal wall healing in rats with postoperative abdominal infection. Bromopride can be used for the study of digestive system diseases (such as gastric hypomotility, nausea and vomiting).
    Bromopride
  • HY-W344044
    Levomepromazine maleate
    Antagonist 99.92%
    Levomepromazine maleate (Methotrimeprazine maleate) is an N-substituted phenylthiazine antipsychotic sedative that blocks multiple receptors. Levomepromazine maleate is a potent inhibitor of CYP2D6 and is useful in the study of schizophreni.
    Levomepromazine maleate
  • HY-111066A
    JNJ-37822681 dihydrochloride
    Antagonist 99.41%
    JNJ-37822681 dihydrochloride is a potent, specific, centrally active, fast-dissociating dopamine D2 receptor antagonist with a moderate binding affinity for the dopamine D2L receptor (Ki =158 nM), which has potential for the treatment of schizophrenia and bipolar disorder.
    JNJ-37822681 dihydrochloride
  • HY-B1019R
    Sulpiride (Standard)
    Antagonist
    Sulpiride (Standard) is the analytical standard of Sulpiride. This product is intended for research and analytical applications. Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer.
    Sulpiride (Standard)
  • HY-106587A
    Octoclothepin maleate salt
    Inhibitor 99.14%
    Octoclothepin maleate salt, an orally active neuroleptic agent, is a dual SR-2A and D2DR inhibitor. Octoclothepin maleate salt reveals an intensive central depressant action in a series of observational and instrumental procedures in rodents.
    Octoclothepin maleate salt
  • HY-14328
    Sonepiprazole
    Antagonist 98.43%
    Sonepiprazole (PNU-101387G) is a selective D4 dopamine antagonist with Kis of 3.6, 10.1, 5147, and 7430 nM for rD4-Dopamine, hD4.2-Dopamine, rD2-Dopamine, and Histamine-H1 receptors, respectively.
    Sonepiprazole
  • HY-121276
    Benperidol
    Inhibitor 99.45%
    Benperidol is a relatively old antipsychotic agent. Benperidol is a butyrophenone antipsychotic, with the highest neuroleptic potency in terms of D2 receptor blockade.
    Benperidol
  • HY-101102
    7-Hydroxy-DPAT hydrobromide
    Inhibitor 99.84%
    7-Hydroxy-DPAT hydrobromide is a selective D3 dopamine receptor agonist, exhibiting significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain.
    7-Hydroxy-DPAT hydrobromide
  • HY-14538R
    Haloperidol (Standard)
    Antagonist
    Haloperidol (Standard) is the analytical standard of Haloperidol. This product is intended for research and analytical applications. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
    Haloperidol (Standard)
  • HY-14958A
    Pardoprunox hydrochloride
    Agonist 99.46%
    Pardoprunox (SLV-308) hydrochloride is a partial dopamine D2 and D3 receptor partial agonist and a serotonin 5-HT1A receptor agonist, with pEC50s of 8, 9.2, and 6.3, respectively.
    Pardoprunox hydrochloride
  • HY-A0163S
    Zuclopenthixol-d4 succinate
    Antagonist ≥99.0%
    Zuclopenthixol-d4 succinate is the deuterium labeled Zuclopenthixol. Zuclopenthixol is a thioxanthene derivative which acts as a mixed dopamine D1/D2 receptor antagonist.
    Zuclopenthixol-d<sub>4</sub> succinate
  • HY-100649
    Hydroxy ziprasidone
    Antagonist 99.53%
    Hydroxy ziprasidone is an impurity of Ziprasidone. Ziprasidone, an antipsychotic agent, is a combined 5-HT (serotonin) and dopamine receptor antagonist.
    Hydroxy ziprasidone
  • HY-A0040
    Talipexole
    Agonist
    Talipexole (B-HT920) is a dopamine agonist that has been proposed as an antiparkinsonian agent.
    Talipexole
  • HY-B0031S
    Quetiapine-d4 fumarate
    Antagonist ≥98.0%
    Quetiapine-d4 (fumarate) is the deuterium labeled Quetiapine fumarate. Quetiapine fumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects.
    Quetiapine-d<sub>4</sub> fumarate
  • HY-14538B
    Haloperidol lactate
    Antagonist
    Haloperidol lactate is a potent antipsychotic agent. Haloperidol lactate can be used in acute and chronic schizophrenia and gilles de la tourette's syndrome. Haloperidol lactate has the potential for the research of psychotic disorders.
    Haloperidol lactate
  • HY-110033
    Ecopipam hydrobromide
    Antagonist ≥99.0%
    Ecopipam (SCH 39166) hydrobromide is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam hydrobromide can be used for the research of schizophrenia and obesity.
    Ecopipam hydrobromide
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.